Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Drucker

Showing results (1-10 of 313) with videos related to

Pageof 32
Sort By:
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Biologic actions and therapeutic potential of the proglucagon-derived peptidesDaniel J Drucker
Nature Clinical Practice. Endocrinology & Metabolism|March 23, 2007
Unraveling the complexities of gut endocrinologyDaniel J Drucker
Diabetes Care|March 6, 2007
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of actionDaniel J Drucker
Endocrinology|June 17, 2006
Enhancing the action of incretin hormones: a new whey forward?Daniel J Drucker
Molecular Metabolism|October 9, 2021
GLP-1 physiology informs the pharmacotherapy of obesityDaniel J Drucker
The Journal of Clinical Investigation|January 16, 2024
The GLP-1 journey: from discovery science to therapeutic impactDaniel J Drucker
Expert Opinion on Investigational Drugs|January 9, 2003
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesDaniel J Drucker
Diabetes Care|August 27, 2011
Incretin-based therapy and the quest for sustained improvements in β-cell healthDaniel J Drucker
Diabetes|July 3, 2013
Incretin action in the pancreas: potential promise, possible perils, and pathological pitfallsDaniel J Drucker
Nature Reviews. Drug Discovery|May 28, 2025
Author Correction: GLP-1-based therapies for diabetes, obesity and beyondDaniel J Drucker
Pageof 32

Showing results (1-10 of 313) with videos related to

Sort By:
Pageof 32
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Biologic actions and therapeutic potential of the proglucagon-derived peptidesDaniel J Drucker
Nature Clinical Practice. Endocrinology & Metabolism|March 23, 2007
Unraveling the complexities of gut endocrinologyDaniel J Drucker
Diabetes Care|March 6, 2007
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of actionDaniel J Drucker
Endocrinology|June 17, 2006
Enhancing the action of incretin hormones: a new whey forward?Daniel J Drucker
Molecular Metabolism|October 9, 2021
GLP-1 physiology informs the pharmacotherapy of obesityDaniel J Drucker
The Journal of Clinical Investigation|January 16, 2024
The GLP-1 journey: from discovery science to therapeutic impactDaniel J Drucker
Expert Opinion on Investigational Drugs|January 9, 2003
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesDaniel J Drucker
Diabetes Care|August 27, 2011
Incretin-based therapy and the quest for sustained improvements in β-cell healthDaniel J Drucker
Diabetes|July 3, 2013
Incretin action in the pancreas: potential promise, possible perils, and pathological pitfallsDaniel J Drucker
Nature Reviews. Drug Discovery|May 28, 2025
Author Correction: GLP-1-based therapies for diabetes, obesity and beyondDaniel J Drucker
Pageof 32